Compared with those in CCM1 and CCM2, mutations in the CCM3 gene are associated with the most severe phenotype, defined as an earlier onset of ICH and concomitance of multiple meningiomas in some cases.
11 A 2-hit mechanism, 13 whereby a germline mutation in 1 allele of a CCM gene is later complemented by a somatic mutation in the other allele, has been described as a trigger in familial CCM. 14 Although CCM is a worldwide disorder, a specific mutation in the CCM1 gene is prevalent in northern New Mexico. The origin of this founder mutation, also known as the common Hispanic mutation-CCM1 , has been traced to a Spanish ancestor who settled in New Mexico in the 1600s. The common Hispanic mutation-CCM1 is responsible for a 15-fold higher population prevalence and is present in virtually all cases of familial CCM in the New Mexico Hispanic population. 15 A founder mutation in the CCM2 gene has been described in the Ashkenazi Jewish population, 16 while no founder
mutations have yet been found in the CCM3 gene. The association between genotype and phenotype in sporadic forms of CCM is less characterized, although the involvement of the same genes is emerging. Mutations in either the CCM1, CCM2, or CCM3 gene have been reported in 57% of sporadic cases with multiple lesions.
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Again, a 2-hit mechanism has been implicated, in which 2 spontaneous somatic mutations occur sequentially at both alleles of 1 of the known CCM genes. 17 Yet other reports suggest a strong association between the presence of cerebral lesions and polymorphisms in the CCM genes in sporadic cases. 18 Whether similar genetic alterations take place in RICM is not yet known. The pathophysiology of RICM has been associated with vascular injury 19 and may lay along a spectrum of radiation-induced vasculopathies that evolve from telangiectasia to CCM.
Clinical Presentation, Natural History, and Current Management of CCM About 60% of CCM lesions present as clinically silent 1 and are discovered incidentally on brain magnetic resonance imaging obtained for other reasons. Sporadic CCM lesions may be associated with a developmentalvenousanomaly, 20 whilefamilialformstypicallypresentwith multiple lesions (even hundreds). In familial patients, modern diagnostic techniques, such as susceptibility-weighted imaging, detect more lesions than were previously identified with T2-weighted gradient echo sequences. 21 These techniques also show that new vascular lesions constantly form de novo with age.
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In symptomatic cases, the most common presentation is seizures, followed by ICH and FND in the absence of an acute hemorrhage.
5
The 5-year risk of first-time seizure in asymptomatic CCM is 4% but increases to 6% in patients presenting with ICH or FND. 23 Reported rates of ICH vary widely in the literature. In 2008, the Angioma Alliance Scientific Advisory Board standardized the definition of CCM-associated ICH. 5 A meta-analysis 24 across 7 patient cohorts using this new definition reported an overall 5-year ICH risk of 15.8%.
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Compared with supratentorial and cerebellar CCMs, lesions located in the brainstem carry the worst prognosis and highest neurologic morbidity, with the combined risk of ICH and FND escalating to more than 50% at 5 years. 24, 25 Moreover, the annual risk of ICH in incidentally discovered or previously asymptomatic CCM is significantly higher in familial (4.3% to 6.5%) 26 compared with sporadic cases (0.08% to 0.1%).
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The clinical approach to CCM depends on presentation, lesion location, and symptom severity ( Figure 1 ). In 2017, the Angioma Alliance Scientific Advisory Board published expert guidelines for clinical management of CCM, 27 and we refer the reader to this publication. Briefly, a 3-generation family history should be collected at the time of diagnosis. Genetic testing, including mutation/deletion analysis of CCM1, CCM2, and CCM3 genes, is recommended in all cases with multiple lesions without a history of radiation exposure or a positive family history. Further genetic counseling should be offered when a mutation is discovered in the proband. Asymptomatic lesions should be managed conservatively with imaging, although routine imaging follow-up is recommended only in the presence of new or worsening symptoms.
27
Cerebral cavernous malformation-related epilepsy is initially treated with antiepileptic drugs until it becomes refractory. Surgery may be offered for medically intractable epilepsy, supported by evidence for early surgical resection of single lesions to obtain durable seizure control. 6 In general, surgery is reserved for symptomatic lesions owing to its intrinsic risk. Postsurgical morbidity and mortality increase after lesion removal from certain locations; those in eloquent/deep areas and brainstem have the highest risk. Because the overall 5-year probability of a second ICH is as high as 29.5%, surgery is recommended after a first symptomatic bleed for lesions in favorable locations. 28 Even in familial cases, for which our understanding of disease progression is more comprehensive, incomplete penetrance and variable presentation within families preclude a reliable risk estimation, 39 hence the necessity for continuous follow-up and/or prompt surgical intervention at the appearance or worsening of symptoms. Nevertheless, our growing knowledge on the natural progression of CCM suggests that there could be a window of opportunity to affect the disease course from time of diagnosis to development of aggressive behavior. In sporadic cases, exploiting this window would control lesion growth and microhemorrhages to limit or abrogate symptomatic ICH and epileptogenesis, which cannot be achieved with current treatment options. Similarly, there is no effective approach to delay lesion growth and de novo formation typical of familial cases, which constantly produce new vascular malformations 22 at a rate that can reach 2.7 per patient per year in the presence of mutations in the CCM3 gene. transition acquire a stem cell-like and mesenchymal cell-like phenotype characterized by loss of proper polarization, increased migration, and decreased cell-cell and cell-matrix adhesion. Consequences of EndMT are abnormal architecture and leakiness of brain blood vessels, and loss of contact between ECs and nervous cells, which ultimately lead to formation of the typical mulberry-shaped cavernae in the context of an angiogenic and inflammatory microenvironment. The molecular mechanisms underlying these biologic and cellular processes have been first studied in iCCM1, an inducible, EC-specific CCM1 knockout transgenic mouse that reproduces the phenotype observed in patients with loss-of-function mutations in the CCM1 gene, namely, lesions within the central nervous system that are composed of dilated multilumen vascular channels with signs of vascular leakage. 49 Brain ECs derived from iCCM1 mice show loss of cell polarity and disruption of cell-cell contacts owing to altered vascular endothelial (VE)-cadherin distribution along with Notch inhibition, 49 which may induce angiogenesis by releasing a negative control on extracellular-signal-regulated kinase 50 and ephrin receptor B4. 51 These cells show hyperactivated EndMT signaling pathways: they overexpress bone morphogenetic protein 6, which leads to hyperactivation of transforming growth factor β receptor with consequent overexpression of β-catenin, increased small mothers against decapentaplegic phosphorylation, and translocation to the nucleus, followed by upregulation of stem cell, inflammatory, and mesenchymal genes including Kruppel-like factor 4 (Klf4) 49 ( Figure 2) . The key role of KLF transcription factors in CCM has been corroborated in an independent mouse model of EC-specific CCM1 gene loss, in which upregulation of Klf2 and Klf4 genes occurs in the early phases of lesion formation, 52 and in mice defective for the CCM2 gene. 53 Likewise, increased KLF2 and FLF4 protein levels have been observed in both familial and sporadic CCM lesions and are considered a hallmark of CCM-related EndMT ( Table 1) . [47] [48] [49] [52] [53] [54] In addition to these observations in CCM1 and CCM2 models, the peculiar phenotype associated with CCM3 gene mutations has been specifically examined in mice with inducible EC-specific loss of CCM3. In these mice, a distinctive tract is an increased exocytosis and secretion of the proangiogenic factor angiopoietin-2 54 ( Figure 2 ), coupled with decreased EC adhesion and pericyte coverage, which causes disorganized blood vessels with enlarged lumen in the cerebellar and retinal venous plexuses. A similar pattern of vessel disorganization associated with high levels of angiopoietin-2 has also been observed in surgical specimens and lesion-derived ECs from patients with CCM3 gene mutations 54 ( Table 1 ).
The question remains as to how these molecular pathways and cellular processes derive from the genetic defects identified in patients with CCM. Quite simply, a loss-of-function mutation in 1 of the CCM genes causes defective production of the homonymous protein. So, the lack of either the CCM1, CCM2, or CCM3 protein is the molecular trigger that ultimately facilitates disease onset. The 3 CCM proteins do not possess intrinsic enzyme activity and are therefore considered as scaffolds or adaptors. 55 When present at normal levels, they bind to each other in the so-called CCM complex, which also includes VE-cadherin, 56 In normal brain endothelial cells (ECs), the 3 CCM proteins form complete CCM and striatin-interacting phosphatase and kinase (STRIPAK) complexes. Under these conditions, cells are properly polarized and tightly connected to each other by vascular endothelial (VE)-cadherin and to the extracellular matrix by β 1 integrin, so cell adhesion prevails over migration. Blood vessels show a properly organized lumen with a continuous endothelial layer. Angiogenesis is inhibited through activation of a Notchmediated negative circuit, exocytosis is restricted by inhibition of Cdc42, and oxidative stress is controlled. Loss of either the CCM1, CCM2, or CCM3 protein disrupts these complexes. The consequent loss of VE-cadherin organization is paralleled by hyperactivation of mitogen-activated protein kinase kinase kinase 3 (MEKK3), RhoA/ Rho-associated protein kinase (ROCK) and Cdc42, overexpression of Kruppel-like factor 2 (KLF2) and KLF4 with induction of transforming growth factor β (TGFβ) signaling, and inhibition of Notch. Brain ECs undergoing endothelial-to-mesenchymal transition (EndMT) lose their physiological adhesion and polarization properties and acquire a migratory phenotype, thus disrupting the endothelial barrier. Increased oxidativestress,exocytosis,inflammationandangiogenesis,anddecreasedautophagy emerge as pathogenic events during CCM lesion formation (in red). Based on these biological premises, preclinical studies and ongoing clinical trials advise the repurposing of several targeted drugs for CCM treatment (in green). ANGPT2 indicates angiopoietin-2; BMP, bone morphogenetic protein; DMH1, dorsomorphin homolog 1; EphB4, ephrin receptor B4; ICAP1, integrin cytoplasmic associated protein-1; MST, mammalian sterile 20-like kinase 3; mTor, mammalian target of rapamycin; SMAD, small mothers against decapentaplegic; TLR-4, toll-like receptor 4. ( Figure 2 ). Collectively, these altered pathways result in loss of cell polarity and decreased cell adhesion associated with disruption of endothelial barrier integrity and abnormal vascular lumen, all events associated with the onset of EndMT ( Table 2) . 52, 53, 57, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] While the presence of CCM1 and CCM2 proteins is restricted to the CCM complex, the CCM3 protein is also found in the striatin-interacting phosphatase and kinase (STRIPAK) complex, where it binds to germinal center kinase III members: mammalian sterile 20-like kinase 3 also known as serine/threonine kinase 24 (STK24), 69 suppressor of kinase 1 (STK25), 67 and mammalian sterile 20-like kinase 4(STK26) 66 ( Figure 2) . Loss of the CCM3 protein and consequent disruption of the STRIPAK complex leads to hyperactivation of Cdc42 69 accompanied by induction of cell migration, 67 alteration of cell polarity, 66 impaired ability to contain oxidative stress, 68 and abnormal exocytosis [62] [63] [64] ( Table 2) , which explains the increased secretion of angiopoietin-2 observed in vivo. 54 Although more studies are needed to dissect the consequences of CCM3 loss-of-function mutations, it seems reasonable that these genetic defects would cause additive effects because the CCM3 protein contributes to both the CCM and STRIPAK complexes. This would explain the extremely severe phenotype observed in patients with loss-of-function mutations of the CCM3 gene.
New Target Inhibitors and Drug Repurposing Undergoing Preclinical or Clinical Investigation
The biological and molecular bases of CCM suggest that specifically dysregulated pathways will yield therapeutic targets (summarized in Table 3 ). 46, [49] [50] [51] 53, [70] [71] [72] [73] [74] [75] [76] From a broader perspective, the CCM proteins regulate biological processes whose dysregulation is also and oxidative stress. 78 The prevalence of these processes implies that specific inhibitors could be effective in the symptomatic treatment of CCM. This hypothesis is confirmed by preclinical studies in which defective autophagy was partially restored by pharmacological inhibition of mammalian target of rapamycin. 70 In addition, the hyperactivation of ERK 50 and EphB4 kinase 51 observed in CCMrelated angiogenesis was reversed by treatment with the smallmolecule inhibitors sorafenib 50 and NVP-BHG712 (NVP), 51 respectively. At the cellular level, EndMT acts as a driving mechanism in CCM lesion onset both in animal models and patients. [46] [47] [48] [49] Consistently, pharmacologic inhibition of transforming growth factor β signaling with dorsomorphin homolog 1 (targeting bone morphogenetic protein), LY364947, SB431542 (targeting small mothers against decapentaplegic), 49 or sulindac (targeting β-catenin) 46 proved effective in reverting the CCM phenotype. The MEKK3-KLF2/4 axis was also successfully targeted with inhibitors of the innate immune receptor toll-like receptor 4, which was incidentally identified as upstream inducer of this signaling pathway in mouse models of gram-negative gut infections. 71 RhoA, whose hyperactivation in CCM has been reported in several in vitro and in vivo studies, is another successful target with the kinase inhibitor fasudil 72, 79 and the indirect inhibitor simvastatin, 53 which normalized vascular permeability and decreased lesion number in transgenic mice. Some of the previously mentioned drugs are already on the market for other applications and could be repurposed with relative ease, namely the mTor inhibitors, sirolimus and everolimus, and the multikinase inhibitor, sorafenib, approved for cancer treatment; sulindac, a nonsteroidal antiinflammatory drug; toll-like receptor 4 inhibitors, originally developed for sepsis treatment; fasudil, a vasodilator used to treat cerebral vasospasm; and simvastatin, a lipidlowering medication. In addition to these rationally designed approaches, other candidates for drug repurposing have emerged from screening studies that assessed marketed drugs in the context of CCM. For example, cholecalciferol (vitamin D 3 ) and tempol (a freeradical scavenger) emerged from a combined in vitro-in vivo screening of 2100 molecules as efficient in reducing lesion burden in Ccm2 transgenic mice. 73 Based on their known pharmacologic action, these compounds would be expected to control CCM progression by inhibiting inflammation and oxidative stress. In another study, 14 of 277 tested compounds were confirmed as inhibitors of MST3/ STK24 kinase activity, 5 of which are already approved by the US Food and Drug Administration or in phase II/III clinical trials for cancer treatment (namely, bosutinib, saracatenib, danusertib, sunitinib, and desatinib). 74 While several compounds are being investigated in preclinical studies, only a few pharmacologic agents have reached clinical testing. The potential efficacy of targeting angiogenesis in CCM is supported by 2 case reports: the observation of incidental resolution in (Figure 1) . A strategy that addresses lesion growth, number, and inherent hemorrhagic potential is needed to alter the disease trajectory in both asymptomatic and symptomatic cases. Indeed, interfering with the natural disease course in CCM would drastically reduce risky surgeries, as well as provide an option to otherwise incurable patients. We propose to exploit the growing knowledge on the molecular biology that underlies CCM to design patient-tailored therapeutics (Figure 2 ). Cerebral cavernous malformation proteins interact, either directly or indirectly, with several cellular partners. Cerebral cavernous malformation 1, CCM2, and CCM3 are components of the CCM complex, while CCM3 is peculiarly included into the STRIPAK complex. Loss of CCM proteins is associated with a disruption of such complexes and activates signaling pathways in brain ECs, eventually leading to lesion formation (Table 1 and Table 2 ). Blocking these dysregulated pathways with targeted inhibitors has proven therapeutic efficacy in animal models and require further investigation. Moreover, several pathologic features of CCM overlap with those observed in cardiovascular diseases and cancer, namely autophagy, angiogenesis, inflammation, and oxidative stress. These commonalities support the feasibility of drug repurposing. In this perspective, 2 pioneering and ongoing clinical trials are evaluating the efficacy of statins to control CCM progression (Table 3) . 
